An Open-Label, Parallel-Group, Single Ascending Dose Study in Healthy Subjects to Evaluate the Safety, Tolerability and Pharmacokinetics of KBP-5074 Following Oral Administration and With a Food Effect Panel

Trial Profile

An Open-Label, Parallel-Group, Single Ascending Dose Study in Healthy Subjects to Evaluate the Safety, Tolerability and Pharmacokinetics of KBP-5074 Following Oral Administration and With a Food Effect Panel

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Aug 2015

At a glance

  • Drugs KBP 5074 (Primary)
  • Indications Diabetic nephropathies; Renal failure
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors KBP Biosciences
  • Most Recent Events

    • 26 Jan 2015 Additional study cohorts 4 and 5 with dose 10 mg and 30 mg were added to the study. Number of treatments arms changed from 3 to 6 as reported by ClinicalTrials.gov record.
    • 26 Jan 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 03 Sep 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top